Clinical trials: Aspergillosis Invasive
Aspergillosis
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.
- Trial name
- NCT00620074
- Testing
- voriconazole, anidulafungin
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Invasive Aspergillosis
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis
The objective of this study is to evaluate the efficacy and safety of intravenous micafungin for the treatment of proven or probable fungal infections caused by Aspergillus sp.
- Trial name
- NCT02646774
- Testing
- Micafungin
- Where
- 19 sites in China
- Volunteers
- 43 people
- Sponsor
- Astellas Pharma China, Inc.
Candidiasis, Esophageal, Candidiasis, Invasive
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
- Conditions
- Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
- Trial name
- NCT01165320
- Testing
- Caspofungin
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Fungal Infections, Invasive Pulmonary Aspergillosis
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA).
- Trial name
- NCT01782131
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis, Mucormycosis
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food…
- Trial name
- NCT04744454
- Testing
- Isauvuconazole group
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Pfizer
Aspergillosis
An Observational Study of Fungal Biomarkers (MK-0000-089)
The purpose of this study is to evaluate the relationship between fungal biomarker levels during anti-fungal therapy and the success of treatment for fungal infection.
- Trial name
- NCT00854607
- Testing
- No Intervention
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Aspergillosis
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
Combination therapy of caspofungin and amphotericin B could be a useful treatment option in invasive fungal disease, but before it can be routinely recommended; carefully controlled and well-designed randomized clinical trials…
- Trial name
- NCT00334412
- Testing
- Ambisome, caspofungin
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Invasive Aspergillosis
F901318 Single Ascending Dose Study in Healthy Male Volunteers
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
- Trial name
- NCT02142153
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Aspergillosis
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
- Trial name
- NCT00047827
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Astellas Pharma Inc
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis/Blood, Aspergillosis/Invasive
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.
- Trial name
- NCT00423163
- Testing
- micafungin, voriconazole
- Where
- 44 sites in United States
- Sponsor
- Astellas Pharma Inc
Mycoses
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A: which are refractory or resistant to…
- Trial name
- NCT00034658
- Testing
- Posaconazole
- Volunteers
- 336 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Invasive Fungal Infections
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
A study to evaluate olorofim (F901318) for the treatment of invasive fungal infections in participants lacking suitable alternative treatment options.
- Trial name
- FORMULA-OLS (NCT03583164)
- Testing
- Olorofim
- Where
- 82 sites in United States, Australia and 15 more
- Volunteers
- 203 people
- Sponsor
- F2G Biotech GmbH
Invasive Pulmonary Aspergillosis
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
- Trial name
- SCYNERGIA (NCT03672292)
- Testing
- SCY-078, Voriconazole
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Scynexis, Inc.
Aspergillosis
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients treated for Invasive Aspergillosis (IA).
- Trial name
- NCT00037206
- Testing
- Anidulafungin, VER002
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Infection, Invasive Fungal
Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)
This retrospective study is designed to provide a consistent method of screening and collecting data on patients who will serve as controls for a comparison of the efficacy of the available antifungal therapies used as salvage…
- Trial name
- NCT00230243
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis, Cryptococcosis
A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections
The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections
- Conditions
- Candidiasis, Cryptococcosis, Aspergillosis
- Trial name
- NCT00647907
- Testing
- Voriconazole
- Where
- 4 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Pfizer